Prasad Nagakumar

Dr. Prasad Nagakumar

Department of Paediatric Respiratory Medicine and Cystic Fibrosis, Birmingham Women’s and Children’s Hospital, Birmingham B4 6NH, UK

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
PDF file
BDBenjamin Davies
Benjamin Davies
PKPriti Kenia
Priti Kenia
PNPrasad Nagakumar
Prasad Nagakumar
AGAtul Gupta
Atul Gupta
Children and young people with asthma need regular monitoring to maintain good asthma control, prevent asthma attacks and manage comorbidities. The COVID‐19 pandemic has resulted in healthcare professionals making fundamental changes to the way healthcare is delivered and for patients and families adapting to these changes. Comprehensive remotely delivered, technology‐based healthcare, closer to the patients home (reducing hospital footfall and possibly reducing carbon footprint) is likely to be one of the important collateral effects of the pandemic. Telemedicine is anticipated to impact everyone involved in healthcare ‐ providers and patients alike. It is going to bring changes to organization, work areas and work culture in healthcare. Healthcare providers, policymakers and those accessing healthcare services will experience the impact of technology‐based healthcare delivery. Telemedicine can play an exciting role in the management of childhood asthma by delivering high‐quality care closer to the child's home. However, unlike adults, children still need to be accompanied by their carers for virtual care. Policymakers will need to take into account potential additional costs as well as the legal, ethical and cultural implications of large scale use of telemedicine. In this narrative review, we review evidence regarding the role of telemedicine and related emerging technologies in paediatric and adolescent asthma. Although there are gaps in the current knowledge, there is evidence demonstrating the important role of telemedicine in management of childhood and adolescent asthma. However, there is an urgent need for healthcare researchers and policymakers to focus on improving the technologies and address the disparities in accessing novel technology‐based management strategies to improve asthma care.

1 November 2020 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
AGAtul Gupta
Atul Gupta
ABAndrew Bush
Andrew Bush
PNPrasad Nagakumar
Prasad Nagakumar

2 October 2021 in iScience
Verified
Journal Article
Open access
ESEleni Syrimi
Eleni Syrimi
EFEanna Fennell
Eanna Fennell
ARAlex Richter
Alex Richter
PVPavle Vrljicak
Pavle Vrljicak
RSRichard Stark
Richard Stark
GTGraham Taylor
Graham Taylor
Multisystem inflammatory syndrome in children (MIS-C) is a life-threatening disease occurring several weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Deep immune profiling showed acute MIS-C patients had highly activated neutrophils, classical monocytes and memory CD8+ T-cells, with increased frequencies of B-cell plasmablasts and double-negative B-cells. Post treatment samples from the same patients, taken during symptom resolution, identified recovery-associated immune features including increased monocyte CD163 levels, emergence of a new population of immature neutrophils and, in some patients, transiently increased plasma arginase. Plasma profiling identified multiple features shared by MIS-C, Kawasaki Disease and COVID-19 and that therapeutic inhibition of IL-6 may be preferable to IL-1 or TNF-α. We identified several potential mechanisms of action for IVIG, the most commonly used drug to treat MIS-C. Finally, we showed systemic complement activation with high plasma C5b-9 levels is common in MIS-C suggesting complement inhibitors could be used to treat the disease.

6 February 2020 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
SISamantha Irving
Samantha Irving
LFLouise Fleming
Louise Fleming
FAFatima Ahmad
Fatima Ahmad
EBElizabeth Biggart
Elizabeth Biggart
YBYvvone Bingham Ba
Yvvone Bingham Ba
ABAndrew Bush
Andrew Bush

13 February 2021 in European Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
PNPrasad Nagakumar
Prasad Nagakumar
CCCeri-Louise Chadwick
Ceri-Louise Chadwick
ABAndrew Bush
Andrew Bush
AGAtul Gupta
Atul Gupta
The COVID-19 pandemic caused by SARS-COV-2 virus fortunately resulted in few children suffering from severe disease. However, the collateral effects on the COVID-19 pandemic appear to have had significant detrimental effects on children affected and young people. There are also some positive impacts in the form of reduced prevalence of viral bronchiolitis. The new strain of SARS-COV-2 identified recently in the UK appears to have increased transmissibility to children. However, there are no large vaccine trials set up in children to evaluate safety and efficacy. In this short communication, we review the collateral effects of COVID-19 pandemic in children and young people. We highlight the need for urgent strategies to mitigate the risks to children due to the COVID-19 pandemic. What is Known:• Children and young people account for <2% of all COVID-19 hospital admissions• The collateral impact of COVID-19 pandemic on children and young people is devastating• Significant reduction in influenza and respiratory syncytial virus (RSV) infection in the southern hemisphere What is New:• The public health measures to reduce COVID-19 infection may have also resulted in near elimination of influenza and RSV infections across the globe• A COVID-19 vaccine has been licensed for adults. However, large scale vaccine studies are yet to be initiated although there is emerging evidence of the new SARS-COV-2 strain spreading more rapidly though young people.• Children and young people continue to bear the collateral effects of COVID-19 pandemic

12 May 2022 in Archives of Disease in Childhood
Verified
Journal Article
Closed access
PDF file
IFI Fullwood
I Fullwood
TET Evans
T Evans
BDBenjamin Davies
Benjamin Davies
TNT Ninan
T Ninan
COC Onyon
C Onyon
PNPrasad Nagakumar
Prasad Nagakumar
Background Medication review is recommended at asthma appointments. The presence of propellant in the metered dose inhalers (MDIs) makes it challenging to identify when the inhaler is empty. The COVID-19 pandemic has resulted in move towards more virtual monitoring of care. We aimed to evaluate if patients identify when the inhaler is empty and the method of inhaler disposal. Methods Prospective, multicentre quality improvement project. Data collected from children with asthma and other respiratory conditions. Outcome measures Children/carers attending hospital were asked how they identify an empty salbutamol inhaler; dose counters in the preventer inhalers and disposal practices were reviewed. Results 157 patients recruited. 125 (73.5%) patients deemed an empty inhaler as either full/partially full. 12 of 66 (18.2%) preventer inhalers with a dose counter were empty. 83% disposed their inhalers in a dustbin. Conclusions Patients cannot reliably identify when their MDI is empty. There is an urgent need for improving inhaler technology and providing appropriate guidance on how to identify when an MDI is empty.